Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib.
Richardson PG, Nagler A, Ben-Yehuda D, Badros A, Hari PN, Hajek R, Spicka I, Kaya H, LeBlanc R, Yoon SS, Kim K, Martinez-Lopez J, Mittelman M, Shpilberg O, Blake P, Hideshima T, Colson K, Laubach JP, Ghobrial IM, Leiba M, Gatt ME, Sportelli P, Chen M, Anderson KC.
Richardson PG, et al. Among authors: kaya h.
EJHaem. 2020 Apr 6;1(1):94-102. doi: 10.1002/jha2.4. eCollection 2020 Jul.
EJHaem. 2020.
PMID: 35847734
Free PMC article.